GenAI-oneers In Insurance

Create a vendor selection project
Click to express your interest in this report
Indication of coverage against your requirements
A subscription is required to activate this feature. Contact us for more info.
Celent have reviewed this profile and believe it to be accurate.
We are waiting for the vendor to publish their solution profile. Contact us or request the RFX.
Projects allow you to export Registered Vendor details and survey responses for analysis outside of Marsh CND. Please refer to the Marsh CND User Guide for detailed instructions.
Download Registered Vendor Survey responses as PDF
Contact vendor directly with specific questions (ie. pricing, capacity, etc)
20 May 2024

How Insurers Are Moving The GenAI Needle


GenAI has rocketed from moonshot to reality. To flesh out the reality for insurers, Celent surveyed insurance executives in roles tied to innovation.

Between March and April 2024, we asked them how their sentiment toward GenAI had changed over the prior year, their state of adoption by area, their view of expected impact by use case, and their technology approach, as well as the key success factors they have identified through their recent experience.

The headline finding of the Celent survey is that the frontrunners are in the early majority phase of adoption (in production) and will move into the late majority phase within a year. This level of tech adoption is exceptional in the annals of insurance.